Germline RAP80 mutations and susceptibility to breast cancer

Mohammad Reza Akbari, Parviz Ghadirian, Andre Robidoux, Maryam Foumani, Yulong Sun, Robert Royer, Inuk Zandvakili, Henry T. Lynch, Steven A. Narod

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Most of the breast cancer susceptibility genes identified to date are involved in DNA repair, including BRCA1, BRCA2, PALB2, CHEK2 and BRIP1. RAP80 works upstream of BRCA1 and is essential for the localization of BRCA1 to the site of damaged DNA. To investigate whether or not RAP80 is also a breast cancer susceptibility gene, we sequenced the entire exonic regions of RAP80 in the germline DNA of 152 women with familial breast cancer, who were previously found to be negative for BRCA1 and BRCA2 mutations. No truncating mutation was identified. Eleven potentially deleterious RAP80 variants were identified; these 11 variants were genotyped in 424 more familial cases and in 726 healthy controls. Three novel p.Ala342Thr, p.Met353Thr and p.Tyr575Asp rare missense variants and a novel haplotype composed of two variants in the CpG island (c.-24149G > T and c.-24001A > G) and a variant in the 5′UTR (c.-8A > G) and a variant in the 3′UTR (c.*27A > C) were detected in 26 of 571 (4.6%) individuals with familial breast cancer, compared to 14 of 725 (1.9%) controls (P = 0.01; OR = 2.4, 95% CI = 1.2-5.1). In summary, we did not find truncating mutations of the RAP80 gene to be a cause of familial breast cancer. A novel RAP80 haplotype or rare missense mutations may be associated with a modest increased risk of breast cancer, but this observation needs to be confirmed by additional studies.

Original languageEnglish
Pages (from-to)377-381
Number of pages5
JournalBreast Cancer Research and Treatment
Volume113
Issue number2
DOIs
StatePublished - Jan 2009

Fingerprint

Germ-Line Mutation
Neoplasm Genes
Breast Neoplasms
Haplotypes
Mutation
CpG Islands
DNA
Missense Mutation
DNA Repair
Genes
Familial Breast Cancer

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Akbari, M. R., Ghadirian, P., Robidoux, A., Foumani, M., Sun, Y., Royer, R., ... Narod, S. A. (2009). Germline RAP80 mutations and susceptibility to breast cancer. Breast Cancer Research and Treatment, 113(2), 377-381. https://doi.org/10.1007/s10549-008-9938-z

Germline RAP80 mutations and susceptibility to breast cancer. / Akbari, Mohammad Reza; Ghadirian, Parviz; Robidoux, Andre; Foumani, Maryam; Sun, Yulong; Royer, Robert; Zandvakili, Inuk; Lynch, Henry T.; Narod, Steven A.

In: Breast Cancer Research and Treatment, Vol. 113, No. 2, 01.2009, p. 377-381.

Research output: Contribution to journalArticle

Akbari, MR, Ghadirian, P, Robidoux, A, Foumani, M, Sun, Y, Royer, R, Zandvakili, I, Lynch, HT & Narod, SA 2009, 'Germline RAP80 mutations and susceptibility to breast cancer', Breast Cancer Research and Treatment, vol. 113, no. 2, pp. 377-381. https://doi.org/10.1007/s10549-008-9938-z
Akbari MR, Ghadirian P, Robidoux A, Foumani M, Sun Y, Royer R et al. Germline RAP80 mutations and susceptibility to breast cancer. Breast Cancer Research and Treatment. 2009 Jan;113(2):377-381. https://doi.org/10.1007/s10549-008-9938-z
Akbari, Mohammad Reza ; Ghadirian, Parviz ; Robidoux, Andre ; Foumani, Maryam ; Sun, Yulong ; Royer, Robert ; Zandvakili, Inuk ; Lynch, Henry T. ; Narod, Steven A. / Germline RAP80 mutations and susceptibility to breast cancer. In: Breast Cancer Research and Treatment. 2009 ; Vol. 113, No. 2. pp. 377-381.
@article{829f47e4fd0347639a3128af2282cb07,
title = "Germline RAP80 mutations and susceptibility to breast cancer",
abstract = "Most of the breast cancer susceptibility genes identified to date are involved in DNA repair, including BRCA1, BRCA2, PALB2, CHEK2 and BRIP1. RAP80 works upstream of BRCA1 and is essential for the localization of BRCA1 to the site of damaged DNA. To investigate whether or not RAP80 is also a breast cancer susceptibility gene, we sequenced the entire exonic regions of RAP80 in the germline DNA of 152 women with familial breast cancer, who were previously found to be negative for BRCA1 and BRCA2 mutations. No truncating mutation was identified. Eleven potentially deleterious RAP80 variants were identified; these 11 variants were genotyped in 424 more familial cases and in 726 healthy controls. Three novel p.Ala342Thr, p.Met353Thr and p.Tyr575Asp rare missense variants and a novel haplotype composed of two variants in the CpG island (c.-24149G > T and c.-24001A > G) and a variant in the 5′UTR (c.-8A > G) and a variant in the 3′UTR (c.*27A > C) were detected in 26 of 571 (4.6{\%}) individuals with familial breast cancer, compared to 14 of 725 (1.9{\%}) controls (P = 0.01; OR = 2.4, 95{\%} CI = 1.2-5.1). In summary, we did not find truncating mutations of the RAP80 gene to be a cause of familial breast cancer. A novel RAP80 haplotype or rare missense mutations may be associated with a modest increased risk of breast cancer, but this observation needs to be confirmed by additional studies.",
author = "Akbari, {Mohammad Reza} and Parviz Ghadirian and Andre Robidoux and Maryam Foumani and Yulong Sun and Robert Royer and Inuk Zandvakili and Lynch, {Henry T.} and Narod, {Steven A.}",
year = "2009",
month = "1",
doi = "10.1007/s10549-008-9938-z",
language = "English",
volume = "113",
pages = "377--381",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Germline RAP80 mutations and susceptibility to breast cancer

AU - Akbari, Mohammad Reza

AU - Ghadirian, Parviz

AU - Robidoux, Andre

AU - Foumani, Maryam

AU - Sun, Yulong

AU - Royer, Robert

AU - Zandvakili, Inuk

AU - Lynch, Henry T.

AU - Narod, Steven A.

PY - 2009/1

Y1 - 2009/1

N2 - Most of the breast cancer susceptibility genes identified to date are involved in DNA repair, including BRCA1, BRCA2, PALB2, CHEK2 and BRIP1. RAP80 works upstream of BRCA1 and is essential for the localization of BRCA1 to the site of damaged DNA. To investigate whether or not RAP80 is also a breast cancer susceptibility gene, we sequenced the entire exonic regions of RAP80 in the germline DNA of 152 women with familial breast cancer, who were previously found to be negative for BRCA1 and BRCA2 mutations. No truncating mutation was identified. Eleven potentially deleterious RAP80 variants were identified; these 11 variants were genotyped in 424 more familial cases and in 726 healthy controls. Three novel p.Ala342Thr, p.Met353Thr and p.Tyr575Asp rare missense variants and a novel haplotype composed of two variants in the CpG island (c.-24149G > T and c.-24001A > G) and a variant in the 5′UTR (c.-8A > G) and a variant in the 3′UTR (c.*27A > C) were detected in 26 of 571 (4.6%) individuals with familial breast cancer, compared to 14 of 725 (1.9%) controls (P = 0.01; OR = 2.4, 95% CI = 1.2-5.1). In summary, we did not find truncating mutations of the RAP80 gene to be a cause of familial breast cancer. A novel RAP80 haplotype or rare missense mutations may be associated with a modest increased risk of breast cancer, but this observation needs to be confirmed by additional studies.

AB - Most of the breast cancer susceptibility genes identified to date are involved in DNA repair, including BRCA1, BRCA2, PALB2, CHEK2 and BRIP1. RAP80 works upstream of BRCA1 and is essential for the localization of BRCA1 to the site of damaged DNA. To investigate whether or not RAP80 is also a breast cancer susceptibility gene, we sequenced the entire exonic regions of RAP80 in the germline DNA of 152 women with familial breast cancer, who were previously found to be negative for BRCA1 and BRCA2 mutations. No truncating mutation was identified. Eleven potentially deleterious RAP80 variants were identified; these 11 variants were genotyped in 424 more familial cases and in 726 healthy controls. Three novel p.Ala342Thr, p.Met353Thr and p.Tyr575Asp rare missense variants and a novel haplotype composed of two variants in the CpG island (c.-24149G > T and c.-24001A > G) and a variant in the 5′UTR (c.-8A > G) and a variant in the 3′UTR (c.*27A > C) were detected in 26 of 571 (4.6%) individuals with familial breast cancer, compared to 14 of 725 (1.9%) controls (P = 0.01; OR = 2.4, 95% CI = 1.2-5.1). In summary, we did not find truncating mutations of the RAP80 gene to be a cause of familial breast cancer. A novel RAP80 haplotype or rare missense mutations may be associated with a modest increased risk of breast cancer, but this observation needs to be confirmed by additional studies.

UR - http://www.scopus.com/inward/record.url?scp=58149216582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149216582&partnerID=8YFLogxK

U2 - 10.1007/s10549-008-9938-z

DO - 10.1007/s10549-008-9938-z

M3 - Article

VL - 113

SP - 377

EP - 381

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -